TORONTO, ONTARIO--(Marketwired - June 27, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the voting results from its annual general meeting held on June 27, 2013. The total number of shares represented in person or by proxy at the meeting was 89,096,694, representing 60.08% of Trimel's total issued and outstanding shares.
Shareholders voted in favour of the reappointment of the auditors of the company, and voted as follows in connection with the election of the directors of the company:
| Name |
Votes For (%) |
Votes Withheld (%) |
| Bruce Brydon |
71,507,481 (81.01%) |
16,763,352 (18.99%) |
| John Friedrichsen |
82,259,608 (93.19%) |
6,011,225 (6.81%) |
| Stephen Gregory |
78,344,206 (88.75%) |
9,926,627 (11.25%) |
| Rolf Reininghaus |
82,245,908 (93.17%) |
6,024,925 (6.83%) |
| Jeffrey Sherman |
78,800,333 (89.27%) |
9,470,500 (10.73%) |
| Dr. D. Lorne Tyrrell |
82,264,608 (93.20%) |
6,006,225 (6.80%) |
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.